Xeris Biopharma stock: Xeris schedules November 5 results for Xeris Biopharma stock

Published on 10/24/2026 at 02:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Xeris Biopharma stock had Q2 revenue of USD 92.10 million. Xeris reports third-quarter results on November 5, 2026 with USD 385-390 million guidance.

Results date and operating scale

Xeris announced on October 22, 2026, that third-quarter results will arrive on November 5, 2026.
Second-quarter revenue reached USD 92.10 million, up 29.00 percent year over year.
Xeris Biopharma Holdings had a USD 1.9 billion market capitalization as of October 23, 2026.

XERS, US98422E1038, Illustration mit AI erstellt.

Xeris Biopharma Holdings (US98422E1038) will publish third-quarter 2026 results on November 5, 2026, after reporting USD 92.10 million in second-quarter revenue. The date was announced on October 22, 2026, by Yahoo Finance.

November 5 brings the next test

The company will report figures for the quarter ended September 30, 2026, before the U.S. market opens and will host a conference call at 8:30 a.m. ET. Management raised the lower end of its full-year 2026 revenue guidance to USD 385 million-390 million after second-quarter performance.

That guidance gives the scheduled report a clear benchmark. In the second quarter, total revenue rose 29.00 percent year over year to USD 92.10 million, while adjusted earnings per share were negative USD 0.18 against consensus of positive USD 0.02, according to Benzinga.

What does the portfolio contribute?

RECORLEV generated USD 56.80 million in second-quarter net revenue, up 81.00 percent year over year. Gvoke contributed USD 22.50 million, up 8.00 percent sequentially, while KEVEYIS generated USD 11.70 million, according to the earnings-call transcript.

The company also presented data from three endocrinology meetings. Business Wire reported on October 15, 2026, that the disclosures covered Gvoke, RECORLEV and the investigational XP-8121 program. The American Thyroid Association meeting is scheduled for November 4-7, 2026, with Xeris data listed for November 6, 2026.

Three recent company milestones

On October 1, 2026, Xeris granted equity awards covering 352,170 shares to 60 new employees, as Business Wire reported. On October 15, the company disclosed data from three scientific meetings. On October 22, it set November 5 as the date for third-quarter results.

Dates for the next catalyst

The next two substantiated dates are November 4-7, 2026, for the American Thyroid Association meeting, and November 5, 2026, for the third-quarter results and conference call. Together, they place operating performance and pipeline evidence in the same reporting window.

Nasdaq valuation sets the market context

XERS last stood at USD 10.20 on Nasdaq on October 23, 2026, at 4:00 p.m. ET. The company had a USD 1.9 billion market capitalization and a 52-week range of USD 5.25 to USD 11.42 on that date.

The further course of trading is shown by the continuously updated real-time quote of Xeris Biopharma stock.